Clinical trials sponsored by Jiangsu HengRui Medicine Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by Jiangsu HengRui Medicine Co., Ltd.

• A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
  NCT06974929 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
  NCT07032688 · Phase: Phase 1 · Ages: 18 Years to 59 Years · Sex: All (male and female) · 1 location
• A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
  NCT07241767 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
  NCT07311694 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
  NCT06689163 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
  NCT06568094 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 2 locations
• A Study of SHR-4394 Injection in Subjects With Prostate Cancer
  NCT06783829 · Phase: Phase 1 · Ages: 18 Years to 85 Years · Sex: Male · 1 location
• A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
  NCT07232849 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
  NCT07003321 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
  NCT06555068 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
  NCT05482568 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
  NCT04316364 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 7 locations
• A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
  NCT07497386 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
  NCT05884255 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
  NCT07232875 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
  NCT07238283 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
  NCT07175220 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
  NCT05942001 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
  NCT06775340 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Jiangsu HengRui Medicine Co., Ltd. recruiting for?

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 19 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.